ANGIOGENESIS AND TUMOR METASTASIS
Angiogenesis, the recruitment of new blood vessels, is an essential component of the metastatic pathway. These vessels provide the principal route by which tumor cells exit the primary tumor site and enter the circulation. For many tumors, the vascular density can provide a prognostic indicator of m...
Gespeichert in:
| Veröffentlicht in: | Annual review of medicine 1998-01, Vol.49 (1), p.407-424 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 424 |
|---|---|
| container_issue | 1 |
| container_start_page | 407 |
| container_title | Annual review of medicine |
| container_volume | 49 |
| creator | Zetter, PhD, Bruce R |
| description | Angiogenesis, the recruitment of new blood vessels, is an essential
component of the metastatic pathway. These vessels provide the principal route
by which tumor cells exit the primary tumor site and enter the circulation. For
many tumors, the vascular density can provide a prognostic indicator of
metastatic potential, with the highly vascular primary tumors having a higher
incidence of metastasis than poorly vascular tumors. Tumor angiogenesis is
regulated by the production of angiogenic stimulators including members of the
fibroblast growth factor and vascular endothelial growth factor families. In
addition, tumors may activate angiogenic inhibitors such as angiostatin and
endostatin that can modulate angiogenesis both at the primary site and at
downstream sites of metastasis. The potential use of these and other natural
and synthetic angiogenic inhibitors as anticancer drugs is currently under
intense investigation. Such agents may have reduced toxicity and be less likely
to generate drug resistance than conventional cytotoxic drugs. Clinical trials
are now underway to develop optimum treatment strategies for antiangiogenic
agents. |
| doi_str_mv | 10.1146/annurev.med.49.1.407 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_2160874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34024657</sourcerecordid><originalsourceid>FETCH-LOGICAL-a524t-7600ea7090edf7e2a0c65e468e63eeda3e94fa9959e3c4533690112c8f785a383</originalsourceid><addsrcrecordid>eNqNkFtLw0AQhRdRaq3-A4UqvibOXrKbfSw11kAvYFrwbVmTDbS0ad1NvPx7tzT6JCIMzMM5Z87wIXSJIcSY8TtdVY01b-HGFCGTIQ4ZiCPUxRGLAkr48zHqAnAeMILlKTpzbgUAktK4gzoyAkkE6aLrwXSUzkbJNMnSrD-Y3vfni8nsqT9J5oPMT5qdo5NSr525aHcPLR6S-fAxGM9G6XAwDnREWB0IDmC0AAmmKIUhGnIeGcZjw6kxhaZGslJLGUlDcxZRyiVgTPK4FHGkaUx76OZwd2e3r41xtVptG1v5SkUI4VQIJryJHUy53TpnTal2drnR9lNhUHsqqqWiPBXFpMLKU_Gxq_Z287IXvkMtBq_ftrp2uV6XVlf50v3YCOYQC-Zt8mDbl-i1r1mad_ffF_7M_pZRu6JU9UdNvwD8zJIh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222637747</pqid></control><display><type>article</type><title>ANGIOGENESIS AND TUMOR METASTASIS</title><source>Annual Reviews</source><source>MEDLINE</source><creator>Zetter, PhD, Bruce R</creator><creatorcontrib>Zetter, PhD, Bruce R</creatorcontrib><description>Angiogenesis, the recruitment of new blood vessels, is an essential
component of the metastatic pathway. These vessels provide the principal route
by which tumor cells exit the primary tumor site and enter the circulation. For
many tumors, the vascular density can provide a prognostic indicator of
metastatic potential, with the highly vascular primary tumors having a higher
incidence of metastasis than poorly vascular tumors. Tumor angiogenesis is
regulated by the production of angiogenic stimulators including members of the
fibroblast growth factor and vascular endothelial growth factor families. In
addition, tumors may activate angiogenic inhibitors such as angiostatin and
endostatin that can modulate angiogenesis both at the primary site and at
downstream sites of metastasis. The potential use of these and other natural
and synthetic angiogenic inhibitors as anticancer drugs is currently under
intense investigation. Such agents may have reduced toxicity and be less likely
to generate drug resistance than conventional cytotoxic drugs. Clinical trials
are now underway to develop optimum treatment strategies for antiangiogenic
agents.</description><identifier>ISSN: 0066-4219</identifier><identifier>EISSN: 1545-326X</identifier><identifier>DOI: 10.1146/annurev.med.49.1.407</identifier><identifier>PMID: 9509272</identifier><identifier>CODEN: ARMCAH</identifier><language>eng</language><publisher>Palo Alto, CA 94303-0139: Annual Reviews</publisher><subject>Angiogenesis ; angiogenesis inhibitors ; Angiostatins ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Blood vessels ; Blood Vessels - pathology ; Breast cancer ; Cancer therapies ; cancer therapy ; Chemotherapy ; Clinical Trials as Topic ; Collagen - adverse effects ; Collagen - physiology ; Collagen - therapeutic use ; Drug Resistance, Neoplasm ; Endostatins ; Endothelial Growth Factors - physiology ; Fibroblast Growth Factors - physiology ; Fibroblasts ; Humans ; Incidence ; invasion ; Medical prognosis ; Medical sciences ; Metastasis ; Neoplasm Metastasis - pathology ; Neoplasm Metastasis - physiopathology ; Neoplasms - blood supply ; Neoplastic Cells, Circulating - pathology ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - pathology ; Peptide Fragments - adverse effects ; Peptide Fragments - physiology ; Peptide Fragments - therapeutic use ; Pharmacology. Drug treatments ; Plasminogen - adverse effects ; Plasminogen - physiology ; Plasminogen - therapeutic use ; Prognosis ; Toxicity ; tumor dormancy ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Annual review of medicine, 1998-01, Vol.49 (1), p.407-424</ispartof><rights>Copyright © 1998 by Annual Reviews Inc. All rights reserved</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Annual Reviews, Inc. 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a524t-7600ea7090edf7e2a0c65e468e63eeda3e94fa9959e3c4533690112c8f785a383</citedby><cites>FETCH-LOGICAL-a524t-7600ea7090edf7e2a0c65e468e63eeda3e94fa9959e3c4533690112c8f785a383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev.med.49.1.407?crawler=true&mimetype=application/pdf$$EPDF$$P50$$Gannualreviews$$H</linktopdf><linktohtml>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev.med.49.1.407$$EHTML$$P50$$Gannualreviews$$H</linktohtml><link.rule.ids>70,314,776,780,4168,27901,27902,77997,77998</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2160874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9509272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zetter, PhD, Bruce R</creatorcontrib><title>ANGIOGENESIS AND TUMOR METASTASIS</title><title>Annual review of medicine</title><addtitle>Annu Rev Med</addtitle><description>Angiogenesis, the recruitment of new blood vessels, is an essential
component of the metastatic pathway. These vessels provide the principal route
by which tumor cells exit the primary tumor site and enter the circulation. For
many tumors, the vascular density can provide a prognostic indicator of
metastatic potential, with the highly vascular primary tumors having a higher
incidence of metastasis than poorly vascular tumors. Tumor angiogenesis is
regulated by the production of angiogenic stimulators including members of the
fibroblast growth factor and vascular endothelial growth factor families. In
addition, tumors may activate angiogenic inhibitors such as angiostatin and
endostatin that can modulate angiogenesis both at the primary site and at
downstream sites of metastasis. The potential use of these and other natural
and synthetic angiogenic inhibitors as anticancer drugs is currently under
intense investigation. Such agents may have reduced toxicity and be less likely
to generate drug resistance than conventional cytotoxic drugs. Clinical trials
are now underway to develop optimum treatment strategies for antiangiogenic
agents.</description><subject>Angiogenesis</subject><subject>angiogenesis inhibitors</subject><subject>Angiostatins</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood vessels</subject><subject>Blood Vessels - pathology</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>cancer therapy</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>Collagen - adverse effects</subject><subject>Collagen - physiology</subject><subject>Collagen - therapeutic use</subject><subject>Drug Resistance, Neoplasm</subject><subject>Endostatins</subject><subject>Endothelial Growth Factors - physiology</subject><subject>Fibroblast Growth Factors - physiology</subject><subject>Fibroblasts</subject><subject>Humans</subject><subject>Incidence</subject><subject>invasion</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Neoplasm Metastasis - pathology</subject><subject>Neoplasm Metastasis - physiopathology</subject><subject>Neoplasms - blood supply</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Peptide Fragments - adverse effects</subject><subject>Peptide Fragments - physiology</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasminogen - adverse effects</subject><subject>Plasminogen - physiology</subject><subject>Plasminogen - therapeutic use</subject><subject>Prognosis</subject><subject>Toxicity</subject><subject>tumor dormancy</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>0066-4219</issn><issn>1545-326X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkFtLw0AQhRdRaq3-A4UqvibOXrKbfSw11kAvYFrwbVmTDbS0ad1NvPx7tzT6JCIMzMM5Z87wIXSJIcSY8TtdVY01b-HGFCGTIQ4ZiCPUxRGLAkr48zHqAnAeMILlKTpzbgUAktK4gzoyAkkE6aLrwXSUzkbJNMnSrD-Y3vfni8nsqT9J5oPMT5qdo5NSr525aHcPLR6S-fAxGM9G6XAwDnREWB0IDmC0AAmmKIUhGnIeGcZjw6kxhaZGslJLGUlDcxZRyiVgTPK4FHGkaUx76OZwd2e3r41xtVptG1v5SkUI4VQIJryJHUy53TpnTal2drnR9lNhUHsqqqWiPBXFpMLKU_Gxq_Z287IXvkMtBq_ftrp2uV6XVlf50v3YCOYQC-Zt8mDbl-i1r1mad_ffF_7M_pZRu6JU9UdNvwD8zJIh</recordid><startdate>19980101</startdate><enddate>19980101</enddate><creator>Zetter, PhD, Bruce R</creator><general>Annual Reviews</general><general>Annual Reviews, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>19980101</creationdate><title>ANGIOGENESIS AND TUMOR METASTASIS</title><author>Zetter, PhD, Bruce R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a524t-7600ea7090edf7e2a0c65e468e63eeda3e94fa9959e3c4533690112c8f785a383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Angiogenesis</topic><topic>angiogenesis inhibitors</topic><topic>Angiostatins</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood vessels</topic><topic>Blood Vessels - pathology</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>cancer therapy</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>Collagen - adverse effects</topic><topic>Collagen - physiology</topic><topic>Collagen - therapeutic use</topic><topic>Drug Resistance, Neoplasm</topic><topic>Endostatins</topic><topic>Endothelial Growth Factors - physiology</topic><topic>Fibroblast Growth Factors - physiology</topic><topic>Fibroblasts</topic><topic>Humans</topic><topic>Incidence</topic><topic>invasion</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Neoplasm Metastasis - pathology</topic><topic>Neoplasm Metastasis - physiopathology</topic><topic>Neoplasms - blood supply</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Peptide Fragments - adverse effects</topic><topic>Peptide Fragments - physiology</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasminogen - adverse effects</topic><topic>Plasminogen - physiology</topic><topic>Plasminogen - therapeutic use</topic><topic>Prognosis</topic><topic>Toxicity</topic><topic>tumor dormancy</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zetter, PhD, Bruce R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Annual review of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zetter, PhD, Bruce R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANGIOGENESIS AND TUMOR METASTASIS</atitle><jtitle>Annual review of medicine</jtitle><addtitle>Annu Rev Med</addtitle><date>1998-01-01</date><risdate>1998</risdate><volume>49</volume><issue>1</issue><spage>407</spage><epage>424</epage><pages>407-424</pages><issn>0066-4219</issn><eissn>1545-326X</eissn><coden>ARMCAH</coden><abstract>Angiogenesis, the recruitment of new blood vessels, is an essential
component of the metastatic pathway. These vessels provide the principal route
by which tumor cells exit the primary tumor site and enter the circulation. For
many tumors, the vascular density can provide a prognostic indicator of
metastatic potential, with the highly vascular primary tumors having a higher
incidence of metastasis than poorly vascular tumors. Tumor angiogenesis is
regulated by the production of angiogenic stimulators including members of the
fibroblast growth factor and vascular endothelial growth factor families. In
addition, tumors may activate angiogenic inhibitors such as angiostatin and
endostatin that can modulate angiogenesis both at the primary site and at
downstream sites of metastasis. The potential use of these and other natural
and synthetic angiogenic inhibitors as anticancer drugs is currently under
intense investigation. Such agents may have reduced toxicity and be less likely
to generate drug resistance than conventional cytotoxic drugs. Clinical trials
are now underway to develop optimum treatment strategies for antiangiogenic
agents.</abstract><cop>Palo Alto, CA 94303-0139</cop><cop>4139 El Camino Way, P.O. Box 10139</cop><cop>USA</cop><pub>Annual Reviews</pub><pmid>9509272</pmid><doi>10.1146/annurev.med.49.1.407</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4219 |
| ispartof | Annual review of medicine, 1998-01, Vol.49 (1), p.407-424 |
| issn | 0066-4219 1545-326X |
| language | eng |
| recordid | cdi_pascalfrancis_primary_2160874 |
| source | Annual Reviews; MEDLINE |
| subjects | Angiogenesis angiogenesis inhibitors Angiostatins Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Blood vessels Blood Vessels - pathology Breast cancer Cancer therapies cancer therapy Chemotherapy Clinical Trials as Topic Collagen - adverse effects Collagen - physiology Collagen - therapeutic use Drug Resistance, Neoplasm Endostatins Endothelial Growth Factors - physiology Fibroblast Growth Factors - physiology Fibroblasts Humans Incidence invasion Medical prognosis Medical sciences Metastasis Neoplasm Metastasis - pathology Neoplasm Metastasis - physiopathology Neoplasms - blood supply Neoplastic Cells, Circulating - pathology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Peptide Fragments - adverse effects Peptide Fragments - physiology Peptide Fragments - therapeutic use Pharmacology. Drug treatments Plasminogen - adverse effects Plasminogen - physiology Plasminogen - therapeutic use Prognosis Toxicity tumor dormancy Tumors Vascular endothelial growth factor |
| title | ANGIOGENESIS AND TUMOR METASTASIS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A15%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANGIOGENESIS%20AND%20TUMOR%20METASTASIS&rft.jtitle=Annual%20review%20of%20medicine&rft.au=Zetter,%20PhD,%20Bruce%20R&rft.date=1998-01-01&rft.volume=49&rft.issue=1&rft.spage=407&rft.epage=424&rft.pages=407-424&rft.issn=0066-4219&rft.eissn=1545-326X&rft.coden=ARMCAH&rft_id=info:doi/10.1146/annurev.med.49.1.407&rft_dat=%3Cproquest_pasca%3E34024657%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222637747&rft_id=info:pmid/9509272&rfr_iscdi=true |